Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 5/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.30 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709321 | 0.99 | NPC1 (0.33) | VDRERAP1ARESR1ESR2 | |
| SCHEMBL13709283 | 0.86 | HDAC3 (0.33) | VDRERAP1AR | |
| SCHEMBL13709332 | 0.85 | HDAC3 (0.33) | VDRERAP1ADORA3 | |
| SCHEMBL13709289 | 0.84 | VDR (0.38) | VDRARESR1ESR2NPC1 | |
| SCHEMBL13709320 | 0.83 | VDR (0.37) | VDRARESR1ESR2NPC1 | |
| SCHEMBL13709299 | 0.83 | VDR (0.34) | VDRERAP1ARESR1ESR2 | |
| SCHEMBL13709287 | 0.82 | USP19 (0.32) | VDRARESR1ESR2NPC1 | |
| SCHEMBL13709330 | 0.82 | VDR (0.34) | VDRERAP1ARADORA3 | |
| SCHEMBL13709337 | 0.82 | NPC1 (0.32) | ARESR1ESR2NPC1RAB9A | |
| SCHEMBL13709279 | 0.81 | ESR1 (0.34) | VDRERAP1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | VDR 1/4885ERAP1 2519/4885AR 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.